Table 3: MIC distributions and activities of vancomycin, teicoplanin, linezolid and tigecycline against the 135 MRSA strains.
No. of strains with MIC (µg ml-1) | MIC50 | MIC90 | % S | |||||||
0.064 | 0.125 | 0.25 | 0.5 | 1 | 2 | 4 | ||||
Vancomycin | 0 | 0 | 2 | 59 | 72 | 2 | 0 | 1 | 1 | 100 |
Teicoplanin | 0 | 2 | 45 | 51 | 28 | 8 | 1 | 0.5 | 1 | 99.2 |
Linezolid | 0 | 0 | 1 | 12 | 55 | 59 | 8 | 1 | 2 | 100 |
Tigecycline | 17 | 46 | 43 | 28 | 1 | 0 | 0 | 0.25 | 0.5 | 99.2 |
MIC50/90, minimum inhibitory concentration which 50%, 90%, respectively of the strains were inhibited.
S: Susceptible.